Academic Industry Partnership for Cancer Research:

Transcription

1 Academic Industry Partnership for Cancer Research: A Facility Design Perspective Presenter Steven Copenhagen, LEED AP CannonDesign Myung Kim, AIA, LEED AP BD+C CannonDesign 1

2 Outline Overarching Trends Bahy Dole Act 1980: Current Drivers Novartis Penn Center for Advanced Cellular Therapies (CACT) Facility Design Drivers and challenges Plan Overview Capabilities / activities Overarching Trends 2

3 The Beginning of Public Private Partnerships Bahy Dole Act of 1980 Driver How best to manage inventions developed through government funding Address missed economic and licensing opportunities Driver Outcome Foster public / private collaborations Promote commercialization of inventions from government funded research Allowed universities and other nonprofit entities to retain patents resulting from work funded by federal grants The Development of Public Private Partnerships What is it? A government service or private business venture that is funded and operated through a partnership of government and one or more private sector companies Also know as PPP, 3P or P3 Why Fundamental Drivers enable the public sector to harness the expertise and efficiencies that the private sector can bring to the delivery of certain facilities and services traditionally procured and delivered by the public sector. partnership is structured so that the public sector body seeking to make a capital investment minimizes its exposure to initial capital borrowing 3

4 Public Private Partnerships Today Current Landscape Grown to include partnerships between academics, healthcare and industry Grown to be more than just a funding mechanisms for projects Benefits Advancing medical science through a time of level spending within the U.S. market Advantages for Academic commercialization of break through discoveries in basic research. (Ideas Generation) Advantages for Industry limiting capital expenditures, capitalizing on external innovative R&D approaches and scientific knowledge in order to expand capacity to address complex disease. (Focus efforts on core strengths) Novartis Penn Medicine Partnership CART Cells Therapy trials for 3 Lymphoid Leukemia patients Complete or partial response No funding The New England Journal of Medicine on August 10, 2011 Going viral Industry s interest Alliance with Novartis Funding toward the CACT The CACT completion by end of the year 2015 Technical transfer Clinical trials Phase II FDA Approval of CTL019 on August 30,

5 Novartis Penn CACT Facility Design 5

6 Drivers and Challenges Program and Growth Process Recruiting and Retention Collaboration and Connection Partner s Environment Strategic Collaboration Abramson Cancer Center Novartis Penn Center for Advanced Cellular Therapies Translational and Correlative Studies Lab Product Development Lab Quality Control Lab Clinical Cell and Vaccine Production Facility Novartis Manufacturing Facility 6

7 Project Information Build Out Program / Size 23,610 SF Labs 6,400 SF Clean Room 4,600 SF cgmp suite (8 Class 7/ISO 10,000 Processing Rooms) 1,800 SF support labs Build Out Schedule 6 months Design from Mar, 2014 to Oct, months Construction from Dec, 2014 to Oct, months cgmp validation from Oct, 2015 to Dec, 2015 Build Out Budget / Cost $27M $800/SF Clean Room Plan Overview Single Corridor Perimeter curtainwall Limited AHU capacity Technology Construction Logistics 7

8 Plan Overview Single Corridor vs. Double Corridor Program changes from 7,600 SF to 6,400 SF Views and daylighting Perimeter curtainwall Double façade All glass (structural glass) system Pre fabricated panel and punched window 8

9 ISPE Annual Meeting 9

10 10

11 Plan Overview Single Corridor Perimeter curtainwall Limited AHU capacity 11,000 cfm 8 ceiling Recirculating FCUs of 22,000 cfm 54 HEPA (42 HEPA in phase 1; and 12 HEPA in phase 2) Technology Wireless Telecommunication Monitoring between BAS and EQ 11

12 Plan Overview Single Corridor Perimeter curtainwall Limited AHU capacity Technology Construction Logistics Hoistway Phasing Minimize downtime during phase 2 Coordinate phase 2 w/ bi annual maintenance Short term program spaces of Media Prep and Gown Out in phase 1 until completion of phase 2 Early occupancy Passenger Elevators and Service Elevators Service circulation Ongoing construction of multiple floors above 12

13 CACT Capabilities / Activities 24 specimens at one time; 400 patients per year 48 specimens at one time in the future Staffed by 100 highly specialized cell therapy professionals Q&A Myung Kim, AIA, LEED AP BD+C Associate Vice President CannonDesign mkim@cannondesign.com Steven Copenhagen, LEED AP Principal CannonDesign scopenhagen@cannondesign.com 13